Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice.
Averin A, Silvia A, Lamerato L, Richert-Boe K, Kaur M, Sundaresan D, Shah N, Hatfield M, Lawrence T, Lyman GH, Weycker D.
Averin A, et al.
Support Care Cancer. 2021 Apr;29(4):2179-2186. doi: 10.1007/s00520-020-05715-3. Epub 2020 Sep 3.
Support Care Cancer. 2021.
PMID: 32880732
Free PMC article.
In the subgroup not receiving first-cycle G-CSF prophylaxis, FN incidence in cycle 1 was 7.8% for HR patients and 4.8% for IR + 1 patients; during the course, corresponding values were 16.9% and 15.9%. Most (> 90%) FN episodes required hospitalization, and mortality ris …
In the subgroup not receiving first-cycle G-CSF prophylaxis, FN incidence in cycle 1 was 7.8% for HR patients and 4.8% for IR + 1 patients; …